New Content  edit
Get The App!

Loading the player...
Prognostic Impact of Molecular Mutations in AML and MDS on Allogeneic Hematopoietic Cell Transplant Outcomes: Adverse Impact of TET2 Mutations
Share URL
Embed Code
Share by Email
Send to social websites
Report this video as inappropriate You can report this video if you think it to be inappropriate, we will review your submission soon. If your reason is not listed here, like copyright infringements, please contact us directly by email. Select your reason
Sexual Content Violent or Repulsive Content
Hateful or Abusive Content Harmful Dangerous Acts
Child Abuse Spam
At ASH 2015, Dr. Betty Hamilton from the Cleveland Clinic discusses her abstract titled "Prognostic Impact of Molecular Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) on Allogeneic Hematopoietic Cell Transplant (HCT) Outcomes: Adverse Impact of TET2 Mutations."